Immune
The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial
Wu J, Zhou L, Liu J, et al. · Crit Care · 2013
PMID: 23327199 · DOI: 10.1186/cc11932
Summary
Multicenter single-blind randomized controlled trial (ETASS) of subcutaneous thymosin alpha 1 vs control in adults with severe sepsis across six tertiary ICUs in China. Primary endpoint: 28-day all-cause mortality.
Citation hosted by NCBI. We link to the source so the researcher can read the abstract, full text, or references-cited list directly.
Compounds referenced in this study
- View product →Thymosin Alpha-1 5mg28-residue acetylated thymic peptide studied in immune-modulation research.
Guides covering this compound
More Immune citations
- The efficacy and safety of thymosin alpha-1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trialBMJ · 2025
- Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trialLiver · 1996
- The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trialJ Viral Hepat · 2005